RU2666995C2 - ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α,25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА - Google Patents

ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α,25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА Download PDF

Info

Publication number
RU2666995C2
RU2666995C2 RU2015102831A RU2015102831A RU2666995C2 RU 2666995 C2 RU2666995 C2 RU 2666995C2 RU 2015102831 A RU2015102831 A RU 2015102831A RU 2015102831 A RU2015102831 A RU 2015102831A RU 2666995 C2 RU2666995 C2 RU 2666995C2
Authority
RU
Russia
Prior art keywords
dihydroxyvitamin
secondary hyperparathyroidism
methylene
serum
levels
Prior art date
Application number
RU2015102831A
Other languages
English (en)
Russian (ru)
Other versions
RU2015102831A (ru
Inventor
Гектор Ф. ДЕЛУКА
Лори А. ПЛАМ
Джулия Б. ЗЕЛЛА
Маргарет КЛАГЕТТ-ДЕЙМ
Original Assignee
Висконсин Алюмни Рисерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2666995(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Висконсин Алюмни Рисерч Фаундейшн filed Critical Висконсин Алюмни Рисерч Фаундейшн
Publication of RU2015102831A publication Critical patent/RU2015102831A/ru
Application granted granted Critical
Publication of RU2666995C2 publication Critical patent/RU2666995C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2015102831A 2012-06-29 2013-03-14 ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α,25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА RU2666995C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29
US61/666,264 2012-06-29
PCT/US2013/031574 WO2014003849A1 (en) 2012-06-29 2013-03-14 USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Publications (2)

Publication Number Publication Date
RU2015102831A RU2015102831A (ru) 2016-08-20
RU2666995C2 true RU2666995C2 (ru) 2018-09-13

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015102831A RU2666995C2 (ru) 2012-06-29 2013-03-14 ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α,25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА

Country Status (19)

Country Link
US (4) US9205096B2 (enExample)
EP (1) EP2866811A1 (enExample)
JP (1) JP2015522015A (enExample)
KR (1) KR20150030673A (enExample)
CN (1) CN104394871A (enExample)
AU (1) AU2013281217B2 (enExample)
BR (1) BR112014032847A2 (enExample)
CA (1) CA2877680C (enExample)
CL (1) CL2014003565A1 (enExample)
CO (1) CO7240358A2 (enExample)
HK (1) HK1206600A1 (enExample)
IL (1) IL236184A0 (enExample)
MX (1) MX2015000076A (enExample)
MY (1) MY172886A (enExample)
NZ (1) NZ703347A (enExample)
RU (1) RU2666995C2 (enExample)
SG (1) SG11201408731WA (enExample)
WO (1) WO2014003849A1 (enExample)
ZA (1) ZA201500119B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2850488C1 (ru) * 2024-10-03 2025-11-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения вторичного гиперпаратиреоза при хронической болезни почек на терминальной стадии почечной недостаточности

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY172886A (en) * 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
WO2015048573A1 (en) 2013-09-27 2015-04-02 Codexis, Inc. Structure based predictive modeling
DK3049973T3 (en) 2013-09-27 2018-10-22 Codexis Inc AUTOMATED SCREENING OF ENZYM VARIENTS
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) * 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
WO2018044468A1 (en) 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US20070191316A1 (en) * 2006-02-02 2007-08-16 Wisconsin Alumni Research Foundation Vitamin d analog - nel, methods and uses thereof
RU2326674C2 (ru) * 2003-09-19 2008-06-20 Пфайзер Продактс Инк. Производные 2-алкилиден-19-нор-витамина d для лечения слабости, поражения мышц или саркопении
US20110034426A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of Preventing Renal Disease and Treating Symptoms Thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
DK1267886T3 (da) 2000-03-27 2006-07-10 Wisconsin Alumni Res Found D-vitaminforbindelser anvendt til at stabilisere nyretransplantater
BR0112454A (pt) * 2000-07-14 2003-07-29 Wisconsin Alumni Res Found Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de composto
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
CA2597624C (en) 2005-02-11 2012-08-14 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
WO2011119610A2 (en) 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1α,25- DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22- DIMETHYL-1α,25-HYDROXYVITAMIN D3
MY172886A (en) * 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2326674C2 (ru) * 2003-09-19 2008-06-20 Пфайзер Продактс Инк. Производные 2-алкилиден-19-нор-витамина d для лечения слабости, поражения мышц или саркопении
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US20070191316A1 (en) * 2006-02-02 2007-08-16 Wisconsin Alumni Research Foundation Vitamin d analog - nel, methods and uses thereof
US20110034426A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of Preventing Renal Disease and Treating Symptoms Thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SLATOPOLSKY E. et al. Effect of 2-methylene-19-nor-(20S)-1-alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism. Journal of bone and mineral research 2007 22(5): 686-94, , с.686, 1-й абзац, фиг.1-3Б, табл.1, раздел Материал и методы. *
SLATOPOLSKY E. et al. Effect of 2-methylene-19-nor-(20S)-1-alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism. Journal of bone and mineral research 2007 22(5): 686-94, реферат, с.686, 1-й абзац, фиг.1-3Б, табл.1, раздел Материал и методы. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2850488C1 (ru) * 2024-10-03 2025-11-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения вторичного гиперпаратиреоза при хронической болезни почек на терминальной стадии почечной недостаточности

Also Published As

Publication number Publication date
CO7240358A2 (es) 2015-04-17
SG11201408731WA (en) 2015-01-29
AU2013281217A1 (en) 2015-01-22
CA2877680C (en) 2017-08-29
US20160136184A1 (en) 2016-05-19
HK1206600A1 (en) 2016-01-15
AU2013281217B2 (en) 2017-03-02
MY172886A (en) 2019-12-13
ZA201500119B (en) 2017-11-29
EP2866811A1 (en) 2015-05-06
US9717744B2 (en) 2017-08-01
US20140187522A1 (en) 2014-07-03
CN104394871A (zh) 2015-03-04
US9034853B2 (en) 2015-05-19
US10046000B2 (en) 2018-08-14
BR112014032847A2 (pt) 2017-06-27
CA2877680A1 (en) 2014-01-03
WO2014003849A1 (en) 2014-01-03
KR20150030673A (ko) 2015-03-20
MX2015000076A (es) 2015-04-10
JP2015522015A (ja) 2015-08-03
US20140005152A1 (en) 2014-01-02
IL236184A0 (en) 2015-01-29
RU2015102831A (ru) 2016-08-20
US20170252360A1 (en) 2017-09-07
NZ703347A (en) 2016-05-27
CL2014003565A1 (es) 2015-08-28
US9205096B2 (en) 2015-12-08

Similar Documents

Publication Publication Date Title
US10046000B2 (en) Use of 2-methylene-19-nor-(20S)-1α,25-Dihydroxyvitamin D3 to treat and prevent secondary hyperparathyroidism in a subject having renal failure
JP6095891B2 (ja) ２５−ヒドロキシビタミンｄ３を含む経口剤形、及び、その経口剤形を週１回ヒトに投与することを含む方法
EP2490695A1 (en) Method of preventing type 1 diabetes
EP2461815B1 (en) Method of preventing renal disease and treating symptoms thereof
US9814736B2 (en) Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism
US10105375B2 (en) Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism
US10369161B2 (en) Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200315